2023年7月7日

N-MOmentum研究新的分析顯示UPLIZNA治療降低患者脊髓損傷形成NMOSD Inebilizumab根據MRI N-MOmentum臨床試驗的數據分析(NCT02200770)治療UPLIZNA (inebilizumab-cdon,地平線療法PLC,都柏林,愛爾蘭)亞臨床減少橫向骨髓炎病灶形成的人視neuromyelitis譜係障礙(NMOSD)與安慰劑相比。研究人員還發現亞臨床病變的形成與未來NMOSD攻擊。結果在歐洲神經病學學會第九屆國會(EAN)。N-MOmentum是一個多中心,雙盲隨機安慰劑對照2/3期臨床試驗的安全性和有效性評估Uplizna NMOSD患者的治療。核磁共振掃描的視神經,大腦/腦幹和脊髓在參與者獲得基線,任何NMOSD攻擊的時候,28周後隨機對照期(RCP),和每年開放部分試驗。RCP結束時,有134名試驗參與者充分neuroaxis MRI掃描和沒有新的報道NMOSD症狀。這個池,20個參與者(15%)顯示脊髓MRI中發現亞臨床病變。病變發生較少在Uplizna-treated參與者與服用安慰劑,小於NMOSD attack-associated病變。此外,病變形成減少使用Uplizna繼續治療。分析研究結果還表明,亞臨床病灶形成脊髓與次年NMOSD襲擊有關。 “This analysis offers new insights into the significance of subclinical MRI findings on the spinal cord as a potential signal of future attacks, adding to the growing list of tools available for physicians to better monitor their patients,” said study author Friedemann Paul, MD. Uplizna is a CD19-directed cytolytic antibody indicated for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. The most common adverse reactions from the therapy were urinary tract infections and arthralgia. The FDA Grants Full Approval for Leqembi for the Treatment of Alzheimer Disease